Inconsistency of HER2 Test Raises Questions
Open Access
- 10 July 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 99 (14) , 1064-1065
- https://doi.org/10.1093/jnci/djm075
Abstract
The tests that determine who gets the powerful breast cancer drug trastuzumab (Herceptin) may not be as reliable as previously thought, researchers reported at the annual meeting of the American Society of Clinical Oncology. That means some women who should be getting trastuzumab treatment are not, while other women who will not benefit are unnecessarily exposed to a drug that can cause heart problems.Keywords
This publication has 0 references indexed in Scilit: